Extensive Tinea Associated with Tofacitinib Therapy Masquerading as New-Onset SCLE

Main Article Content

Connor R Buechler
Wayne State University School of Medicine

Elena Kurland
Department of Dermatology, Henry Ford Health System

Jesse Veenstra
Department of Dermatology, Henry Ford Health System

Keywords

tinea corporis, tinea capitis, trichophyton, dermatophytosis, tofacitinib, Janus kinase inhibitor

Abstract

Rheumatoid arthritis is a chronic autoimmune disorder that often requires treatment with immunomodulatory agents, however, such interventions are not without risk of opportunistic infection.  Monitoring for such conditions is critical, whereas recognition and treatment can prove challenging at times, as they may manifest with an atypical presentation or masquerade as another condition entirely. We present here a case of extensive tinea corporis with concomitant tinea capitis masquerading as new-onset connective tissue disorder in a patient being treated for rheumatoid arthritis with the Janus kinase inhibitor tofacitinib.

References

1. Xeljanz medication guide. United Stated Food and Drug Administration. Updated May, 2018. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/203214s018lbl.pdf. Accessed April 18, 2020.

2. Chen, Y., Gong, F. Y., Li, Z. J., Gong, Z., Zhou, Z., Ma, S. Y., & Gao, X. M. (2017). A study on the risk of fungal infection with tofacitinib (CP-690550), a novel oral agent for rheumatoid arthritis. Scientific reports, 7(1), 1-9.

3. Winthrop, K. L., Park, S. H., Gul, A., Cardiel, M. H., Gomez-Reino, J. J., Tanaka, Y., ... & Riese, R. (2016). Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis. Annals of the rheumatic diseases, 75(6), 1133-1138.

4. Bardazzi, F., Balestri, R., Rech, G., Antonucci, A., & Patrizi, A. (2011). Dermatophytosis during anti‐TNF‐α monoclonal antibody therapy. Mycoses, 54(5), e619-e620.

5. Pirker, I. F., Krane-Nuber, J., Albrich, W. C., Müller, R., & Neumann, T. (2018). Atypical presentation of Pneumocystis jirovecii pneumonia in a patient with rheumatoid arthritis treated with tofacitinib: a case presentation. BMC rheumatology, 2(1), 34.

6. Waheed, I., Dhingani, D., Srinivasan, L., & Fulambarker, A. (2016). Double-Edged Sword: Disseminated Histoplasmosis In Rheumatoid Arthritis Patient On Tofacitinib Therapy. In D48. LUNG INFECTION CASE REPORTS I: FUNGAL INFECTIONS (pp. A7121-A7121). American Thoracic Society.

7. Bachelez, H., Van de Kerkhof, P. C., Strohal, R., Kubanov, A., Valenzuela, F., Lee, J. H., ... & Gupta, P. (2015). Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial. The Lancet, 386(9993), 552-561.

8. Crispin, M. K., Ko, J. M., Craiglow, B. G., Li, S., Shankar, G., Urban, J. R., ... & Marinkovich, M. P. (2016). Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata. JCI insight, 1(15).

9. Craiglow, B. G., & King, B. A. (2015). Tofacitinib citrate for the treatment of vitiligo: a pathogenesis-directed therapy. JAMA dermatology, 151(10), 1110-1112.

10. Levy, L. L., Urban, J., & King, B. A. (2015). Treatment of recalcitrant atopic dermatitis with the oral Janus kinase inhibitor tofacitinib citrate. Journal of the American Academy of Dermatology, 73(3), 395-399.

11. Newland, J. G., & Abdel-Rahman, S. M. (2009). Update on terbinafine with a focus on dermatophytoses. Clinical, cosmetic and investigational dermatology: CCID, 2, 49.

Article Sidebar

PDF
Published
Aug 26, 2020
DOI https://doi.org/10.25251/skin.4.5.13

Article Details

How to Cite
Buechler, C. R., Kurland, E., & Veenstra, J. (2020). Extensive Tinea Associated with Tofacitinib Therapy Masquerading as New-Onset SCLE. SKIN The Journal of Cutaneous Medicine, 4(5), 456–459. https://doi.org/10.25251/skin.4.5.13
Issue
Vol. 4 No. 5 (2020): September Issue & Poster Presentations (FCPANP20® Dermatology Conference)
Section
Brief Articles
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.